Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-Hodgkin lymphoma in common variable immunodeficiency.

C Cunningham-Rundles1, P Lieberman, G Hellman

  • 1Department of Medicine, Mount Sinai Medical Center, New York, New York 10029.

American Journal of Hematology
|June 1, 1991
PubMed
Summary

Individuals with common variable immunodeficiency (CVI) have an increased risk of developing non-Hodgkin lymphoma (NHL). These lymphomas share features with childhood immunodeficiency-associated lymphomas but may be more differentiated and occur in adults.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rheumatologic diseases in patients with inborn errors of immunity in the USIDNET registry.

Clinical rheumatology·2022
Same author

Gut T cell-independent IgA responses to commensal bacteria require engagement of the TACI receptor on B cells.

Science immunology·2020
Same author

Chemical chaperones reverse early suppression of regulatory circuits during unfolded protein response in B cells from common variable immunodeficiency patients.

Clinical and experimental immunology·2019
Same author

Research abstracts presented at the Eastern Allergy Conference, Palm Beach, Florida, May 6-9, 2010.

Allergy and asthma proceedings·2017
Same author

Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis.

Allergy·2017
Same author

Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

Clinical and translational allergy·2017

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • The link between immunodeficiency and cancer is well-documented.
  • Common Variable Immunodeficiency (CVI) is characterized by low immunoglobulins and impaired antibody production.
  • Previous studies reported 13 cancers in 11 CVI patients, including 7 non-Hodgkin lymphomas (NHL).

Purpose of the Study:

  • To investigate the histologic, immunologic, cytogenetic, and clinical features of NHL in CVI patients.
  • To compare NHL in CVI with lymphomas seen in other childhood immunodeficiency syndromes.
  • To understand the characteristics and prognosis of NHL in CVI.

Main Methods:

  • Histologic, immunologic, and cytogenetic analysis of 8 previously identified NHL cases and 3 new lymphoma cases in CVI patients.

Related Experiment Videos

  • Comparison of lymphoma features in CVI with those in Wiskott Aldrich Syndrome, Ataxia Telangiectasia, and severe combined immunodeficiency.
  • Clinical observation of a cohort of 117 CVI patients.

    • Main Results:

    • Lymphomas in CVI share similarities with childhood immunodeficiency lymphomas in frequency (13%), B-cell origin, and extranodal location.
    • Unlike childhood cases, CVI-associated lymphomas can be more differentiated and secrete immunoglobulin.
    • NHL in CVI predominantly affects adult females (5th-7th decade) and has a good prognosis for early-stage disease.
    • Cytogenetic abnormalities, including chromosomal translocations, are present in some CVI lymphomas, but further research is needed.

    Conclusions:

    • Lymphomas in CVI patients exhibit distinct characteristics compared to those in childhood immunodeficiencies.
    • Early-stage NHL in CVI patients generally has a favorable prognosis.
    • Further cytogenetic studies are required to determine the frequency and significance of chromosomal abnormalities in CVI-associated lymphomas.